KR950701217A - 향전이제로서 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido derivatives useful as antimetastaic agents) - Google Patents
향전이제로서 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido derivatives useful as antimetastaic agents)Info
- Publication number
- KR950701217A KR950701217A KR1019940703947A KR19940703947A KR950701217A KR 950701217 A KR950701217 A KR 950701217A KR 1019940703947 A KR1019940703947 A KR 1019940703947A KR 19940703947 A KR19940703947 A KR 19940703947A KR 950701217 A KR950701217 A KR 950701217A
- Authority
- KR
- South Korea
- Prior art keywords
- bis
- methyl
- pyrrole
- carbonyl
- carbonylimino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 230000001394 metastastic effect Effects 0.000 claims abstract 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 125000000542 sulfonic acid group Chemical group 0.000 claims abstract 2
- -1 carbonylimino Chemical group 0.000 claims 41
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 7
- FKORGLNGEASTQE-UHFFFAOYSA-N naphthalene-1,3-disulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 FKORGLNGEASTQE-UHFFFAOYSA-N 0.000 claims 3
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- ZPBSAMLXSQCSOX-UHFFFAOYSA-N naphthalene-1,3,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=CC2=CC(S(=O)(=O)O)=CC=C21 ZPBSAMLXSQCSOX-UHFFFAOYSA-N 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000002001 anti-metastasis Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- FEWNRIKJXAQRJJ-UHFFFAOYSA-N naphthalene-1,3,7-trisulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 FEWNRIKJXAQRJJ-UHFFFAOYSA-N 0.000 claims 1
- FMHFHTQXVYDQRT-UHFFFAOYSA-N naphthalene-1,4,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 FMHFHTQXVYDQRT-UHFFFAOYSA-N 0.000 claims 1
- BBCBMZZXCBYNRL-UHFFFAOYSA-N naphthalene-1,6,7-trisulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=C2C=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC2=C1 BBCBMZZXCBYNRL-UHFFFAOYSA-N 0.000 claims 1
- HEWDOWUUTBCVJP-UHFFFAOYSA-N naphthalene-1,6-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 HEWDOWUUTBCVJP-UHFFFAOYSA-N 0.000 claims 1
- HYFMZOAPNQAXHU-UHFFFAOYSA-N naphthalene-1,7-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 HYFMZOAPNQAXHU-UHFFFAOYSA-N 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
- FITZJYAVATZPMJ-UHFFFAOYSA-N naphthalene-2,6-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(S(=O)(=O)O)=CC=C21 FITZJYAVATZPMJ-UHFFFAOYSA-N 0.000 claims 1
- VILFVXYKHXVYAB-UHFFFAOYSA-N naphthalene-2,7-disulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=CC2=CC(S(=O)(=O)O)=CC=C21 VILFVXYKHXVYAB-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939304589A GB9304589D0 (en) | 1993-03-05 | 1993-03-05 | Biologically active ureido derivatives useful as antimetastic agents |
| GB9304589.6 | 1993-03-05 | ||
| PCT/EP1994/000268 WO1994020095A1 (en) | 1993-03-05 | 1994-01-31 | Biologically active ureido derivatives useful as antimetastatic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950701217A true KR950701217A (ko) | 1995-03-23 |
Family
ID=10731580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940703947A Withdrawn KR950701217A (ko) | 1993-03-05 | 1994-01-31 | 향전이제로서 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido derivatives useful as antimetastaic agents) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5534539A (enExample) |
| EP (1) | EP0639073A1 (enExample) |
| JP (1) | JPH07506594A (enExample) |
| KR (1) | KR950701217A (enExample) |
| CN (1) | CN1103533A (enExample) |
| AU (1) | AU669269B2 (enExample) |
| CA (1) | CA2134098A1 (enExample) |
| FI (1) | FI945164A7 (enExample) |
| GB (1) | GB9304589D0 (enExample) |
| HU (1) | HUT71400A (enExample) |
| IL (1) | IL108665A (enExample) |
| MY (1) | MY110004A (enExample) |
| NZ (1) | NZ261308A (enExample) |
| PL (1) | PL305981A1 (enExample) |
| TW (1) | TW262465B (enExample) |
| WO (1) | WO1994020095A1 (enExample) |
| ZA (1) | ZA941126B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
| GB9504065D0 (en) * | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Poly-pyrrolecarboxamidonaphthalenic acid derivatives |
| GB9602721D0 (en) * | 1996-02-09 | 1996-04-10 | Pharmacia Spa | Biologically active ureido derivatives useful in the treatment of multiple sclerosis |
| WO1999027939A1 (en) | 1997-12-04 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation |
| GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| AU3980499A (en) * | 1998-05-11 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Use of neomycin for treating angiogenesis-related diseases |
| MXPA04006709A (es) * | 2002-01-11 | 2004-10-04 | Sankyo Co | Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen. |
| KR20110136901A (ko) | 2004-02-24 | 2011-12-21 | 상꾜 가부시키가이샤 | 아미노 알코올 화합물 |
| EP3381897A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer |
| CN107235866B (zh) | 2017-06-13 | 2019-09-10 | 重庆医科大学 | 一种用于检测次磺酸化蛋白质的荧光探针、制备方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5012285A (en) * | 1984-10-12 | 1986-05-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
| CA1308516C (en) * | 1987-07-06 | 1992-10-06 | The Governors Of The University Of Alberta | Oligopeptide anticancer and antiviral agents |
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| GB9024738D0 (en) * | 1990-11-14 | 1991-01-02 | Erba Carlo Spa | A new method of treatment of tumor necroisis factor(tnf)-related diseases |
| GB9116896D0 (en) * | 1991-08-06 | 1991-09-18 | Erba Carlo Spa | 3-deoxymannosamine derivatives and process for their preparation |
| GB9216962D0 (en) * | 1992-08-11 | 1992-09-23 | Erba Carlo Spa | Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives |
-
1993
- 1993-03-05 GB GB939304589A patent/GB9304589D0/en active Pending
-
1994
- 1994-01-31 NZ NZ261308A patent/NZ261308A/en unknown
- 1994-01-31 EP EP94906181A patent/EP0639073A1/en not_active Ceased
- 1994-01-31 CN CN94190108A patent/CN1103533A/zh active Pending
- 1994-01-31 AU AU60003/94A patent/AU669269B2/en not_active Ceased
- 1994-01-31 CA CA002134098A patent/CA2134098A1/en not_active Abandoned
- 1994-01-31 WO PCT/EP1994/000268 patent/WO1994020095A1/en not_active Ceased
- 1994-01-31 JP JP6519502A patent/JPH07506594A/ja active Pending
- 1994-01-31 KR KR1019940703947A patent/KR950701217A/ko not_active Withdrawn
- 1994-01-31 PL PL94305981A patent/PL305981A1/xx unknown
- 1994-01-31 HU HU9403177A patent/HUT71400A/hu unknown
- 1994-02-16 IL IL108665A patent/IL108665A/xx not_active IP Right Cessation
- 1994-02-18 ZA ZA941126A patent/ZA941126B/xx unknown
- 1994-03-03 MY MYPI94000512A patent/MY110004A/en unknown
- 1994-03-04 TW TW083101900A patent/TW262465B/zh active
- 1994-11-02 FI FI945164A patent/FI945164A7/fi unknown
-
1995
- 1995-06-12 US US08/489,621 patent/US5534539A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07506594A (ja) | 1995-07-20 |
| IL108665A (en) | 1997-03-18 |
| NZ261308A (en) | 1996-02-27 |
| PL305981A1 (en) | 1995-02-20 |
| TW262465B (enExample) | 1995-11-11 |
| US5534539A (en) | 1996-07-09 |
| FI945164A0 (fi) | 1994-11-02 |
| IL108665A0 (en) | 1994-05-30 |
| ZA941126B (en) | 1994-08-30 |
| AU6000394A (en) | 1994-09-26 |
| CN1103533A (zh) | 1995-06-07 |
| GB9304589D0 (en) | 1993-04-21 |
| FI945164A7 (fi) | 1994-11-02 |
| AU669269B2 (en) | 1996-05-30 |
| EP0639073A1 (en) | 1995-02-22 |
| WO1994020095A1 (en) | 1994-09-15 |
| CA2134098A1 (en) | 1994-09-15 |
| HUT71400A (en) | 1995-11-28 |
| MY110004A (en) | 1997-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920701150A (ko) | 폴리-4-아미노-2-카복시-1-메틸 화합물의 신규한 우레이도 유도체 | |
| KR960034164A (ko) | 스틸벤 유도체 및 이를 함유하는 약제학적 조성물 | |
| KR930019637A (ko) | 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 | |
| CA2230082A1 (en) | Amide compounds and use thereof | |
| KR890013035A (ko) | 인돌로카르바졸 유도체와 그 제조방법 및 그들을 함유하는 약제조성물 | |
| KR930019655A (ko) | 종양치료 조성물 및 치료방법 | |
| DK613686D0 (da) | Antimykotisk virksom neglelak og fremgangsmaade til dens fremstilling | |
| DK0530505T3 (da) | Hydantoinderivater | |
| ATE63124T1 (de) | Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung. | |
| CA2238859A1 (en) | Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them | |
| HU914153D0 (en) | Electrically operated lock | |
| EA200100516A1 (ru) | Производные 3,3-биарилпиперидина и 2,2-биарилморфолина | |
| DE3575554D1 (de) | Aminosaeurederivate mit antitumoraktivitaet sowie diese derivate enthaltende zusammensetzungen. | |
| KR850000451A (ko) | 결정성 나트륨 아목시실린의 제조방법 | |
| KR890005088A (ko) | 4- 아미노피리딘 유도체 및 그의 산 부가염 | |
| KR970706251A (ko) | 항종양제 및 항바이러스제로서의 비스-(2-할로에틸)아미노페닐 치환된 디스타마이신 유도체(Bis-(2-haloethyl)aminophenyl substituted distamycin derivatives as antitumor and antiviral agents) | |
| KR930017885A (ko) | 항종양 조성물 및 종양의 치료방법 | |
| DE69330601D1 (de) | Serotoninergische ergolin derivate | |
| RU93004535A (ru) | Соединения, способ получения и фармацевтическая композиция на их основе | |
| AU641686B2 (en) | Benzanilides | |
| EP0604352A3 (en) | Aryl substituted heterocyclic compounds. | |
| IL108665A (en) | Pharmaceutical compositions containing ureido derivatives of substituted pyrroles, certain such novel compounds and their preparation | |
| KR930023338A (ko) | 데포우 제제 | |
| DE69329184D1 (de) | Alkylsubstituierte heterocyclische Verbindungen | |
| IE33371L (en) | Protozoacids; aminoguanidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19941105 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 19961228 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |